Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 20, 2024 08:05 ET
Bridger Aerospace Responds to Concerns Over Politically Motivated Attacks on its Business
Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today responded to questions from various constituencies as a result of...
May 20, 2024 08:05 ET
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today...
May 20, 2024 08:01 ET
BPMC Alert: The Law Firm of Andrews & Springer LLC Is Investigating Blueprint Medicines Corporation For Potential Securities Violations and Breaches of Fiduciary Duty
The law firm of Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders, is investigating potential securities violations and breach of fiduciary duty claims against Blueprint Medicines Corporation...
May 20, 2024 08:01 ET
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other...
May 20, 2024 08:01 ET
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, unveiled key findings from its groundbreaking eAArly DETECT study during a poster presentation at the renowned Digestive...
May 20, 2024 08:00 ET
“Breaking Points” Podcast Launches on Rumble
Rumble, the video-sharing platform (NASDAQ: RUM) and cloud services provider, today announced that the podcast “Breaking Points” is making Locals and Rumble its new subscription provider. The full show will be available to paying community members...
May 20, 2024 08:00 ET
ABM Recognized as One of the Best Places to Work in Healthcare
ABM (NYSE: ABM), a leading provider of integrated facility services, infrastructure solutions, and parking management, has been recognized as one of the 2024 Best Places to Work in Healthcare by Modern Healthcare. This is the seventh time ABM has...
May 20, 2024 08:00 ET
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal...
May 20, 2024 08:00 ET
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
APRINOIA Therapeutics (“Aprinoia” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases, today announced that on May 8, 2024, the U.S....
May 20, 2024 08:00 ET
authID to Hold Annual Meeting of Stockholders on June 26th
authID® [Nasdaq: AUID] a leading provider of innovative biometric identity verification and authentication solutions, today announced that its 2024 Annual Meeting of Stockholders will be held virtually on June 26, at 10:00 a.m. EDT. At the...
May 20, 2024 08:00 ET
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and...
May 20, 2024 08:00 ET
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will be hosting a webcasted...
May 20, 2024 08:00 ET
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will participate in a panel at the 2024 BIO International Convention, taking...
May 20, 2024 08:00 ET
CervoMed to Appoint William Elder as Chief Financial Officer
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will...
May 20, 2024 08:00 ET
Coca-Cola Consolidated Announces Commencement of Tender Offer to Purchase up to $2.0 Billion in Value of its Common Stock
Coca-Cola Consolidated, Inc. (NASDAQ: COKE) (the “Company”) announced today that it has commenced a modified “Dutch auction” tender offer to purchase shares of its Common Stock for an aggregate purchase price of up to $2.0 billion. Pursuant to...
May 20, 2024 08:00 ET
Dave Cantin Group Introduces First-Ever AI-Powered Data-Mining Software to Accurately Value the Nation’s 18,000+ Franchise Dealerships
Using its new AI-powered data-mining software, retail automotive advisory firm Dave Cantin Group (DCG) can now provide accurate, reliable data-driven valuations for any new-car dealership in the United States, regardless of brand, location or...
May 20, 2024 08:00 ET
Discover the Newest Way to Create Punchy, Flavorful Beverages
Today, John I. Haas, Inc. (HAAS®), renowned leader in the global hops industry, announces the release of their bold, new, flavor and aroma product: Euphorics™ – a revelry of hops and other botanicals. Euphorics is a highly concentrated,...
May 20, 2024 08:00 ET
Genius Group Announces Exercise of Warrants for $3.8 Million Gross Proceeds
Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered education group, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series 2024-C warrants to...
May 20, 2024 08:00 ET
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a...
May 20, 2024 08:00 ET
Hopebridge Continues to Grow Autism Therapy Services by Opening Two New Locations in North Carolina
As the prevalence of autism increases and the national focus is placed on early identification and intervention, Hopebridge Autism Therapy Centers is bringing its innovative mix of multidisciplinary services closer to home for Wilmington and...